Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Nov 2006

Hubner Richard A, Muir Kenneth R, Liu Jo-Fen, Logan Richard F A, Grainge Matthew, Armitage Nicholas, Shepherd Vic, Popat Sanjay, Houlston Richard S

Abstract excerpt

PURPOSE: The UDP glucuronosyltransferase 1A6 (UGT1A6) and cytochrome P450 2C9 (CYP2C9) enzymes participate in the metabolism of nonsteroidal anti-inflammatory drugs, endogenous substances, and carcinogens. Functional polymorphisms of UGT1A6 (T181A and R184S) and CYP2C9 (R144C and I359L) have been reported to modify the protective effect of aspirin on colorectal adenoma risk. We aimed to further investigate the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoma
Share to Anti-Inflammatory Agents, Non-Steroidal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aspirin

Share to Colorectal Neoplasms

Share to Glucuronosyltransferase

Share to Neoplasm Recurrence, Local

Share to Polymorphism, Genetic

Share to Risk Factors

Source

Identifiers

PMID: 17085674
DOI: 10.1158/1078-0432.CCR-06-0903

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence.PMID 17085674Read ↗

The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma.Semantic proximity Read ↗

CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment.Semantic proximity Read ↗

Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention.Semantic proximity Read ↗

Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial.Semantic proximity Read ↗

Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention.Semantic proximity Read ↗

MTHFR genotype and colorectal adenoma recurrence: data from a double-blind placebo-controlled clinical trial.Semantic proximity Read ↗

Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: colon cancer family registry.Semantic proximity Read ↗

Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.Semantic proximity Read ↗

Folate metabolism polymorphisms influence risk of colorectal adenoma recurrence.Semantic proximity Read ↗

Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations.Semantic proximity Read ↗

Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants.Semantic proximity Read ↗

Polymorphisms in PTGS1, PTGS2 and IL-10 do not influence colorectal adenoma recurrence in the context of a randomized aspirin intervention trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.